Main > ENDOCRINOLOGY > Diabetes. Treatment > SitaGliptin (DPP-IV Inhibitor) > Co.: USA. M. (Brand/Tablet/Patents)

---

Co.: USA. M. (Brand/Tablet/Patents)'s subsections
Company
DPP = DiPeptidyl Peptidase
MonoTherapy (Approved)
Patent>DisClosure
Patent>Total USA No.: 1
Patent>UpDate: 01.30.07
Patent>US Expiration: 07.05.2022
Side Effects>Pancreatitis
Sitagliptin Phosphate
Structural IUPAC Name
Synthesis>Rh Catalyzed Hydrog.>
TradeMark
Type 2 Diabetes
USA>Approval Date: 10.17.2006
Web-Site

Co.: USA. M. (Brand/Tablet/Patents)'s products
This section has no products